Le Lézard
Classified in: Health
Subjects: PDT, FDA

La Roche-Posay Changes The Face Of Acne With Latest FDA Approved Acne Ingredient And Premieres Artificial Intelligence-Based Skin Analysis


NEW YORK, July 10, 2019 /PRNewswire/ -- La Roche-Posay is committed to improving access to dermatological care for people with acne, which affects over 50 million Americans. La Roche-Posay announces the launch of Effaclar Adapalene Gel 0.1% Acne Treatment, containing adapalene, a prescription-strength retinoid acne treatment, now available over-the-counter. La Roche-Posay is also launching My Skin Track PoreScan, their first skin analysis powered by artificial intelligence. La Roche-Posay is providing consumers new and innovative tools developed with dermatologists to address their skin concerns.

Over the past 3 decades, OTC (over-the-counter) acne treatments have been limited to only a handful of active ingredients, mostly with benzoyl peroxide and salicylic acid. These ingredients are widely used by consumers, as the vast majority of people with acne don't consult a dermatologist to get a prescription.

La Roche-Posay now offers a topical prescription-strength retinoid (adapalene) acne treatment in addition to its award-winning Effaclar Duo micronized benzoyl peroxide acne treatment. The American Academy of Dermatology (AAD) describes topical retinoids and benzoyl peroxide as first line treatments for mild to severe acne.

"There are many effective acne prescriptions including combinations of benzoyl peroxide and topical retinoids. However, many don't have access to these prescriptions because they don't visit a dermatologist or their insurance won't cover it. OTC prescription-strength acne treatments are a game-changer for people who have limited access to a health care provider. It allows earlier access to treatment which can help prevent scarring." - Hilary Baldwin, MD, Board Certified Dermatologist

Along with skincare, La Roche-Posay believes better-looking skin starts with a personalized skin analysis and skincare regimen. Recognizing that many consumers are confused about which products are right for their skin type and concern, La Roche-Posay is launching My Skin Track PoreScan. This tool uses artificial intelligence to make personalized skincare recommendations for those concerned with clogged pores, raised imperfections, and residual marks

"My Skin Track PoreScan not only provides consumers access to a personalized skincare regimen upon their initial skin analysis, but it also allows them to track changes in their skin after completing their regimen. This will provide insights into how to adapt their daily skincare routine with new product recommendations based on their new needs." ? Adrien Dissous, VP of Maketing for La Roche-Posay USA

To create this innovative tool, La Roche-Posay partnered with dermatologists from around the world to analyze more than 6,000 images of men and women of multiple ethnicities, ages, and skin types. My Skin Track PoreScan was presented at the Worldwide Congress of Dermatology in June of 2019.

About LA ROCHE-POSAY
Recommended by 90,000 dermatologists worldwide, La Roche-Posay's mission is to offer a better life for sensitive skin. Created by a pharmacist in 1975, the brand is now present in over 60 countries. It offers a unique range of daily skincare developed for every skin type to complement their patients' treatments and promote good skincare practices adapted to each skin concern. The brand develops formulas with its exclusive Selenium-rich water, also used at its Thermal Center, the first Dermatology Center in Europe, due to its antioxidant and soothing properties. The products are developed using a strict formulation charter with a minimal number of ingredients and are formulated at optimal concentrations. Additionally, La Roche-Posay products undergo stringent clinical testing for efficacy and safety, even on sensitive skin. The key La Roche-Posay product ranges are: Lipikar (dry skin), Anthelios (photoprotection), Effaclar (acne) and Toleriane (sensitive skin).

For additional information about La Roche-Posay, visit www.laroche-posay.us and follow La Roche-Posay USA on Facebook, Instagram and Twitter @LaRochePosayUSA

La Roche-Posay Declares Most Successful Sun Safety Year Yet (PRNewsfoto/La Roche-Posay)

SOURCE La Roche-Posay


These press releases may also interest you

at 08:40
PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") , a biotechnology company focused on the research, development, and manufacturing of LaNeotm MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that, further...

at 08:33
Prescient Healthcare Group, a leading biopharma product and portfolio strategy firm, has announced the appointment of two new members to its Board of Directors ? Dr. Luke Solon and Debbie Allman ? to help shape and drive Prescient's global mission....

at 08:31
Snufff, the innovative nasal inhaler, emerges onto the wellness and lifestyle scene, offering a refreshing blend of enjoyment and health benefits. Crafted in the vibrant heart of Singapore, Snufff aims to revolutionize the way we approach personal...

at 08:31
Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") , a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it filed its annual report on Form 20-F for the...

at 08:15
MGI Tech, a company committed to building core tools and technology to lead life science, is proud to announce that its DNBSEQ-T20x2* gene sequencer has been recognized with a Gold Edison Award in the "Health, Medical & Biotech" category....

at 08:05
Antibe Therapeutics Inc. ("Antibe" or the "Company") announced that the Company sought an extension of its previously announced stay of proceedings ("Stay") under the Companies' Creditors Arrangement Act (the "CCAA") at a hearing before the Ontario...



News published on and distributed by: